Association for Accessible Medicines

The Association for Accessible Medicines (AAM), Washington, D.C., is a trade association representing the manufacturers and distributors of generic prescription drugs, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the U.S. generic drug industry. As the primary lobby for makers of generic drugs,[1] AAM's stated mission is to advocate for public policies that facilitate timely access to lower-cost, FDA-approved generic and biosimilar medicines by consumers and patients. Over the 10-year period 2008 through 2018, the use of generic drugs generated $2 trillion in U.S. healthcare savings.[2]

Prior to February 2017, AAM was the Generic Pharmaceutical Association (GPhA).[3]

  1. ^ Pear, Robert. “Top Pharmaceutical Lobbyist Threads A Thicket of Outrage“ Archived 2023-05-20 at the Wayback Machine, The New York Times, 26 February 2016. Retrieved on 15 July 2016.
  2. ^ IQVIA. “2019 Generic Drug and Biosimilars Access & Savings in the U.S. Report” Archived 2024-06-26 at the Wayback Machine
  3. ^ "Introducing the New Association for Accessible Medicines (AAM)". Association for Accessible Medicines. Archived from the original on 24 April 2017. Retrieved 1 May 2017.